Advertisement

SRNE

Sorrento Therapeutics, Inc.

USD

Set alert

Price alert · SRNE

All alert types
0.00 USD 0.00 0.00%
As of Oct 30, 2026
0.009 Day range 0.01
0.0001 52-week range 0.009
YTD
-88.46%
1 year
-96.05%
Open
0.009
Prev close
0.0003
Mkt cap
165.38K
Vol
501.68K
Avg vol
80.52K
EPS
-0.67
P/E
0.00
Div yield
0.00%
More statistics
Low
0.009
High
0.01
Forward P/E
-0.45
Beta
0.00
Dividend
0.00
Ex-div date
Earnings
Oct 4, 2024
50-d avg
0.817524
200-d avg
1.58
1y target
13.00

2Y chart

Chart tools
Interval
SRNE two-year price chart0.000.020.050.070.10Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
168.36M
Trailing P/E
0.00
Forward P/E
-0.45
Price / sales
0.00
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
0
Total cash
0
Total debt
0
Return on equity
0.00%
50-day average
0.817524
200-day average
1.58

Analyst view

Consensus: buy

Buy
Price target (mean) 13.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Oct 4, 2024

Expected Oct 4, 2024. Consensus EPS estimate -0.19.

Earnings history

Earnings

SRNE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 4, 2024Jun 1, 20240.00———
Jul 1, 2024Mar 1, 20240.00———
Feb 28, 2023Dec 1, 2022-0.19———
Nov 8, 2022Sep 1, 2022-0.25-0.20+0.05+20.00%
Aug 15, 2022Jun 1, 2022-0.23-0.31-0.08-34.78%
May 5, 2022Mar 1, 20220.00———

Upgrades / downgrades

SRNE analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2022Cantor Fitzgeraldinit—Overweight
Mar 25, 2022HC Wainwright & Co.main—Buy
Aug 9, 2021HC Wainwright & Co.main—Buy
Jan 21, 2021Alliance Global Partnersinit—Buy
Jul 31, 2020HC Wainwright & Co.main—Buy
May 26, 2020Dawson Jamesinit—Buy

News

Your note

Sign in to keep a note on SRNE — it syncs with the Stock Master app.

Insider holders

SRNE insider holders
InsiderRelationLatest transactionDateShares held
ABG MANAGEMENT, LTD.Beneficial Owner of more than 10% of a Class of SecuritySaleSep 12, 20180
ASGHAR NAJJAMChief Financial OfficerStock Award(Grant)Mar 15, 202156,974
ASIA PACIFIC MEDTECH BVI, LTD.Beneficial Owner of more than 10% of a Class of SecuritySaleJan 23, 20188,617,510
FOLLOWWILL DORMANDirectorSaleDec 15, 20202,130
JANDA KIM DDirectorSaleDec 26, 20213,000
JI HENRY HChief Executive OfficerConversion of Exercise of derivative securityDec 20, 20220

Institution ownership

SRNE institution ownership
Holder% heldSharesValueReported
State Street Corporation10.73%50,637,57115.56MDec 30, 2022
Blackrock Inc.8.35%39,423,64112.11MDec 30, 2022
Vanguard Group, Inc. (The)6.26%29,535,9549.08MDec 30, 2022
Geode Capital Management, LLC1.89%8,905,9362.74MDec 30, 2022
B. Riley Financial, Inc.1.11%5,216,2501.60MDec 30, 2022
B. Riley Securities, Inc.1.11%5,216,2501.60MDec 30, 2022

Fund ownership

SRNE fund ownership
Holder% heldSharesValueReported
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF8.66%40,885,07012.56MDec 30, 2022
Vanguard Total Stock Market Index Fund2.72%12,843,7253.95MSep 29, 2022
iShares Russell 2000 ETF2.20%10,359,4263.18MDec 30, 2022
Vanguard Extended Market Index Fund1.17%5,513,2431.69MSep 29, 2022
Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh0.91%4,270,7811.31MDec 30, 2022
iShares Russell 2000 Value ETF0.87%4,113,6081.26MDec 30, 2022
Advertisement